Apo-Semaglutide Recall: What Telehealth Patients Should Ask Their Provider and Pharmacy

The recall

Apotex recalled lot 7000636A of its Apo-Semaglutide 1 mg-dose pen on September 23, 2026. Health Canada says pens from that lot may show and deliver 0.25 mg or 0.5 mg instead of 1 mg.

• Product: Apo-Semaglutide injection, 1 mg-dose pen (4 mg/pen), DIN 02568012, 1.34 mg/mL
• Affected lot: 7000636A
• Recall date: September 23, 2026 (Health Canada reference RA-82679, Type II, retail depth)
• Distribution: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Ontario and Quebec

Who contacts you when medication is prescribed online?

With telehealth, the prescriber and the dispensing pharmacy are often different organizations, and a recall notice may not reach you directly. So check yourself: read the lot number on your pen or box.

Questions worth asking

• Which pharmacy dispensed my pen, and which manufacturer made it?
• Is my lot affected? Can the pharmacist confirm it?
• Who do I call for a replacement, and how quickly?
• Does my provider need to review my dose plan if I received a lower dose than intended?

If your lot is 7000636A, do not stop your medication on your own. Speak to your pharmacist or prescriber first. Report side effects to Health Canada.

Check the provider serves you

The affected lot was distributed in seven provinces. If you live in Quebec, remember that telehealth there is regulated separately, and some national platforms do not serve it.